Mental Health Clinics in New Milford, NJ Accepting Medicare
4 Mental Health Clinics found. Showing 1 - 4
 New Hope Psychotherapy Lcsw Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 245 Azalea Dr, New Milford, NJ 07646 Phone: 646-481-4485 |
The Healing Hour, Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1005 Carnation Dr, New Milford, NJ 07646 Phone: 201-644-6523 |
Welcoming Waves Wellness, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 567 Princeton St, New Milford, NJ 07646 Phone: 646-732-3142 |
Mindspa Therapeutic Wellness Center Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 146 Seminole Ave, New Milford, NJ 07646 Phone: 973-271-8273 |
News Archive
Chelsea completes successful NORTHERA pre-NDA assessment with FDA
Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.
Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo
Immune Network Ltd. advises that Ukrainian company Ekomed LLC has agreed to collaborate with Immune Network and Immunitor for further clinical research of a tableted form of Ekomed's well-known immunomodulator herbal product Immunoxel/Dzherelo.
Researchers analyze how in-person learning would impact transmission in schools' communities
Since early in the COVID-19 pandemic, parents, teachers, and school administrators have faced difficult questions regarding when and how to safely reopen for in-person learning.
Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients
The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.
› Verified 3 days ago